Blood Cancer - Shenzhen Genoimmune Medical Institute

Blood Cancer

Trial title

Estimated Enrollment

Partner
Trial title

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies' NCT03050190

Estimated Enrollment

200

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20,20,38, and 123 Targeting Hematological Malignancies' NCT03125577

Estimated Enrollment

200

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma' NCT03271632

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multi-center Phase I/II Clinical Trial of Multi-CART Cell Therapy for Acute Myeloid Leukemia' NCT03222674

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia' NCT04016129

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multi-center Phase I/II Clinical Trial of Multiple CAR T Cells for Treating Acute Myeloid Leukemia' NCT04010877

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies' NCT04033302

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Multi-center Phase I/II Clinical Trial of 4SCAR-CD44v6 T Cells for Treating Cancer' NCT04427449

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas' NCT04429438

Estimated Enrollment

11

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia' NCT04430530

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma' NCT04637503

Estimated Enrollment

100

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL' NCT05262673

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL' NCT05277753

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

CD19/22 Bi-specific CAR-T Cells Targeting B Cell Malignancies' NCT05432882

Estimated Enrollment

60

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

CD19/70 Bi-specific CAR-T Cells Targeting B Cell Malignancies' NCT05436496

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies' NCT05436509

Estimated Enrollment

60

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

4SCAR19U T Cells Targeting B Cell Malignancies' NCT05995015

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Universal 4SCAR7U Targeting CD7-positive Malignancies' NCT05995028

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Universal CAR-T Cells Targeting Multiple Myeloma' NCT06006741

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Universal CAR-T Cells Targeting AML' NCT05995041

Estimated Enrollment

30

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy' NCT06429150

Estimated Enrollment

20

Partner
- Shenzhen Geno-immune Medical Institute
Trial title

Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients' NCT06435910

Estimated Enrollment

10

Partner
- Shenzhen Geno-immune Medical Institute